Back to top
more

Annovis Bio (ANVS)

(Real Time Quote from BATS)

$9.06 USD

9.06
626,048

+0.70 (8.37%)

Updated May 15, 2024 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals

by Zacks Equity Research

Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.

Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated

by Zacks Equity Research

Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.

Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues

by Zacks Equity Research

Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.

Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.

Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research

Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.

Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues

by Zacks Equity Research

Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.

Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises

by Zacks Equity Research

Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.

Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.

Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

by Zacks Equity Research

Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

by Zacks Equity Research

Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

by Zacks Equity Research

Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.

Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

by Zacks Equity Research

Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

by Zacks Equity Research

Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.

DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch

by Zacks Equity Research

DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.

Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals

by Zacks Equity Research

Intra-Cellular (ITCI) jumps 23% after achieving key goals in the late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

by Zacks Equity Research

Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

by Zacks Equity Research

Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up

by Zacks Equity Research

RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

by Zacks Equity Research

Candel (CADL) rallies 43% as the FDA grants the orphan drug designation to its lead candidate, CAN-2409, for treating non-metastatic pancreatic cancer.

Eyenovia (EYEN) Down 18% on Disappointing Corporate Update

by Zacks Equity Research

Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

by Zacks Equity Research

Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.

Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.